z-logo
open-access-imgOpen Access
C-reactive protein and procalcitonin - laboratory markers of degrees of severity and complications of an acute necrotic pancreatitis
Author(s) -
Oleksandr Rotar,
Igor Khomiak,
Vasyl Rotаr,
Andrii Khomiak,
S. I. Railianu
Publication year - 2020
Publication title -
klìnìčna hìrurgìâ/klìnìčna hìrurgìâ
Language(s) - English
Resource type - Journals
eISSN - 2522-1396
pISSN - 0023-2130
DOI - 10.26779/2522-1396.2020.3-4.14
Subject(s) - procalcitonin , medicine , acute pancreatitis , c reactive protein , sepsis , septic shock , gastroenterology , prospective cohort study , pancreatitis , apache ii , systemic inflammatory response syndrome , intensive care unit , inflammation
Objective. To conduct comparative estimation of efficacy of C-reactive protein and procalcitonin as laboratory markers for stratification of the patients severity state suffering an acute necrotic pancreatitis. Materials and methods. Prospective cohort investigation, including 151 patients with an acute necrotic pancreatitis, was conducted. Clinical, laboratory and bacteriological investigations were accomplished. The levels of C-reactive protein and procalcitonin were determined in the blood plasm. Results. The necrotic accumulations infectioning was diagnosed in 89 (58.9%) patients: local purulent complications - in 27, sepsis - in 33,septic shock - in 29. In 62 patients with sterile pancreonecrosis a C-reactive protein concentration have raised from (5.6 ± 0.89) to (206 ± 29) mg/l (p˂0.001). Development of purulent-septic complications was accompanied by significant and trustworthy (p<0.01) elevation of procalcitonin concentration: in the patients with sepsis - up to (5.05 ± 0.92) ng/ml, in the patients with septic shock - up to (7.25 ± 2.15) ng/ml. Conclusion. Simultaneous measurement of levels of C-reactive protein and procalcitonin in the blood plasm in patients, suffering acute necrotic pancreatitis, gives permission to determine the inflammatory process character and stratify the disease severity in its early terms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here